Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06973304 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

StatusRecruiting
PhasePhase 3
SponsorTakeda
Started2025-06-26
View on ClinicalTrials.gov ↗
The main aim of the study is to assess how well teduglutide works over 24 weeks in Chinese adult participants with short bowel syndrome (SBS) who need parenteral support and to see how much it can reduce the amount of parenteral support and understand how the body absorbs, processes, and gets rid of teduglutide. Participants will receive a daily injection of teduglutide under the skin for 24 weeks. Safety of teduglutide will be checked for 24 weeks after treatment. Participants will be in the study for about 65 weeks.

Amendment record

Amended 5 times since 2025-05-08; most recent filed 2026-06-19. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-06-19
Amendment Study Status, Contacts/Locations, References v5
2025-07-03
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v4
2025-06-18
Amendment Study Status v3
2025-06-02
Amendment Study Status, Contacts/Locations v2
2025-05-21
Amendment Study Status, References v1
2025-05-08
Original filing
Trial Details
NCT Number NCT06973304
Lead Sponsor Takeda
Conditions Short Bowel Syndrome
Enrollment 13 participants
Start Date 2025-06-26
Primary Completion 2027-02-10 (estimated)
Study Completion 2027-07-28 (estimated)
Updated on ClinicalTrials.gov 2026-06-24